Evidence map›Paper›PMID 34121166›Full record

ArticleAnnals of nuclear medicine2021

Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.

Hiroyuki Tatekawa, Hiroyuki Uetani, Akifumi Hagiwara, Shadfar Bahri, Catalina Raymond, Albert Lai, Timothy F Cloughesy, Phioanh L Nghiemphu, Linda M Liau, Whitney B Pope and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 2 countries.

Hiroyuki TatekawaUCLA Brain Tumor Imaging Laboratory (BTIL), David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Hiroyuki UetaniDepartment of Radiological Science, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Akifumi HagiwaraUCLA Brain Tumor Imaging Laboratory (BTIL), David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Shadfar BahriDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, 924 Westwood Blvd., Suite 615, Los Angeles, CA, 90024, USA.
Catalina RaymondUCLA Brain Tumor Imaging Laboratory (BTIL), David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Albert LaiUCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Timothy F CloughesyUCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Phioanh L NghiemphuUCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Linda M LiauUCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Whitney B PopeDepartment of Radiological Science, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Noriko SalamonDepartment of Radiological Science, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA.
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory (BTIL), David Geffen School of Medicine, University of California Los Angeles, Los Angeles, USA. bellingson@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-2764-6640
University of California, Los Angeles · US

Funding

American Brain Tumor Association (ABTA) Research Collaborators Grant ARC1700002American Cancer Society (ACS) Research Scholar Grant RSG-15-003-01-CCENIH/NCI 1R21CA223757-01NIH/NCI UCLA Brain Tumor SPORE 1P50CA211015-01A1
6 · The paper itself

Abstract

objectiveThe association of overall survival (OS) with tumor burden, including contrast enhanced (CE) volume on CE T1-weighted images, fluid-attenuated inversion recovery (FLAIR) hyperintense volume, and 3, 4-dihydroxy-6-[

methodsThirty-four patients with treatment-naïve IDH wild-type gliomas (WHO grade II 6, III 15, IV 13) were retrospectively included. Three pre-operative tumor regions of interest (ROIs) were segmented based on the CE, FLAIR hyperintense, and FDOPA hypermetabolic regions. Resected ROIs were segmented from the post-operative images. Residual CE, FLAIR hyperintense, and FDOPA hypermetabolic ROIs were created by subtracting resected ROIs from pre-operative ROIs. Cox regression analysis was conducted to investigate the association of OS with the volume of each ROI, and Akaike information criterion was used to assess the fitness.

resultsResidual CE volume had a significant association with OS [hazard ratio (HR) = 1.26, p = 0.039], but this effect disappeared when controlling for tumor grade. Residual FDOPA hypermetabolic volume best fit the regression model and was significantly associated with OS (HR = 1.18, p = 0.008), even when controlling for tumor grade. FLAIR hyperintense volume showed no significant association with OS.

conclusionResidual FDOPA hypermetabolic burden predicted OS for IDH wild-type gliomas, regardless of the tumor grade. Furthermore, removing hypermetabolic and CE regions may improve the prognosis.

Indexed as

Brain NeoplasmsGliomaIsocitrate DehydrogenaseTumor BurdenAdultAgedDihydroxyphenylalanineFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesDihydroxyphenylalaninefluorodopa F 18Isocitrate Dehydrogenase18F-DOPA PETBiological tumor burdenIDH wild-type diffuse gliomaPrognosis

Identifiers

PMID34121166
OpenAlexW3122679379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.